Hebrew University professor wins 2013 Award for Outstanding Achievement in Chemistry in Cancer Research

NewsGuard 100/100 Score

The American Association for Cancer Research (AACR) has chosen Prof. Alexander Levitzki of the Hebrew University of Jerusalem as the winner of its 2013 Award for Outstanding Achievement in Chemistry in Cancer Research.

The AACR is currently holding its annual meeting through Wednesday in Washington, D.C.

Levitzki, professor of biological chemistry at the Alexander Silberman Institute of Life Sciences at the Hebrew University, will deliver his award lecture there on Tuesday afternoon on "Eradicating Tumors by Targeting Nonviral Vectors Carrying PolyIC."

The AACR said that Levitzki was chosen for the honor in recognition of his contributions to signal transduction therapy and his work on the development of tyrosine kinase inhibitors as effective agents against cancer.

Levitzki's concept of targeted cancer therapy using protein tyrosine kinase inhibitors is extensively used by the pharmaceutical industry worldwide to develop anticancer drugs. His studies formed the basis for the development of drugs like imatinib, crizotinib and lapatinib, used for the treatment of patients with chronic myeloid leukemia, lung cancer and breast cancer, respectively. Currently there are more than 200 such inhibitors at various stages of the U.S. Food and Drug Administration's approval process.

His method of large-scale screening of synthetic compounds tested against a large spectrum of protein kinases for specificity, followed by systematic testing in cell lines and animal studies, became the standard procedure in most of the laboratories working in that field.

Source: The Hebrew University of Jerusalem

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Medically aided conception vs. natural conception: Study explores cancer risk in children